Targeted Alpha Therapy of Prostate Cancer

Prostate cancer (PC) is now the second most common cause of death from cancer in men after lung cancer (1 ). Brachytherapy, prostatectomy, or external beam radiation can effect a cure, with a life expectancy of at least 10 yr at diagnosis (2 ). Survival depends on the disease being organ confined, specimen confined, or margin positive, with failure rates of 12, 30, and 60%, respectively. Despite aggressive therapy, a significant percentage of men will die of disseminated disease (3 ). Moreover, radical therapy can have distressing side effects. ranging from surgical mortality, incontinence, impotence, bowel damage, and stricture (4 ).